Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9539
-0.0761-7.39%
Volume:4.88M
Turnover:4.77M
Market Cap:264.33M
PE:-8.58
High:1.05
Open:1.03
Low:0.9500
Close:1.03
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:0.55
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:10.57
PE(LYR):-45.90

Loading ...

Akebia Therapeutics Q1 Revenue USD 53.5 Million VS. Ibes Estimate USD 51.7 Million

THOMSON REUTERS
·
May 07

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Akebia Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 05

Akebia grants new hires options for 208,800 shares at $1.38 each

Reuters
·
May 05

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 05

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

GlobeNewswire
·
May 04

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
May 01

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 29

Akebia Therapeutics (AKBA) Gets a Buy from Piper Sandler

TIPRANKS
·
Apr 24

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 16

Akebia doses first participants in Phase 1 trial of AKB-9090 for acute kidney injury

Reuters
·
Apr 13

Akebia Therapeutics Inc - Akb-097 to Enter Phase 2 Basket Trial in Rare Kidney Diseases in Second Half of 2026

THOMSON REUTERS
·
Apr 13

Akebia Therapeutics Inc - Top Line Data From Phase 1 Trial Expected in Early 2027

THOMSON REUTERS
·
Apr 13

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

GlobeNewswire
·
Apr 07

Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside

TIPRANKS
·
Apr 07

Akebia Therapeutics Price Target Maintained With a $4.00/Share by BTIG

Dow Jones
·
Apr 07

Piper Sandler Sticks to Their Buy Rating for Akebia Therapeutics (AKBA)

TIPRANKS
·
Apr 06

H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA)

TIPRANKS
·
Apr 06

Akebia Therapeutics director Philip J. Vickers files initial beneficial ownership statement

Reuters
·
Apr 04